Common medications may help lower dementia risk, according to a new analysis of health data.
Researchers reviewed medical records from over 130,000 older adults in the United Kingdom and found that several widely used drugs were associated with a reduced likelihood of developing dementia over time. The study, published in a leading medical journal, examined the long-term use of medications for conditions such as high blood pressure, diabetes, and depression.
Among the findings, individuals who took certain antihypertensive drugs — particularly ACE inhibitors and angiotensin receptor blockers — showed a lower incidence of dementia compared to those who did not. Similarly, some diabetes medications, including metformin, were linked to decreased risk, especially when used consistently over several years.
Antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs), also appeared in the analysis as having a potential protective association, though researchers noted the relationship requires further study to rule out confounding factors such as underlying depression severity.
The study did not prove causation, but the observed associations remained significant after adjusting for age, genetics, lifestyle factors, and other health conditions. Experts caution that these medications should not be started solely for dementia prevention without medical advice, as each carries potential side effects and risks.
Nonetheless, the results add to growing evidence that managing vascular and metabolic health may play a role in brain aging. With dementia affecting millions worldwide and no cure currently available, identifying accessible, low-cost strategies to delay onset is a public health priority.
Researchers said the findings could inform future clinical guidelines and encourage doctors to consider brain health when prescribing common treatments for chronic conditions. They emphasized that lifestyle factors like exercise, diet, and cognitive engagement remain critical components of dementia prevention.
The study was conducted by scientists at the University of Oxford and supported by public health funding bodies in the UK. Data came from the Clinical Practice Research Datalink, a large-scale database of anonymized patient records from general practices across the country.
